Quell Therapeutics Raises $156 million in Oversubscribed Ser

- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad

Related Keywords

Boston , Massachusetts , United States , Paris , France General , France , United Kingdom , London , City Of , British , Eleanor Perkin , Frazer Hall , Luke Henry , Iain Mcgill , Martin Murphy , Dwayne Holman , Kostenloser Wertpapierhandel , Phouman Ashrafian , Christina Tartaglia , Linkedin , Stern Investor Relations Inc , Sv Health Investors , Syncona Investment Management , Tekla Capital Management , Fidelity Management Research Company , Syncona Ltd , Prnewswire Quell Therapeutics Ltd , Jeito Capital , Ridgeback Capital Investments , Fidelity Management , Research Company , Therapeutics Ltd , British Patient Capital , Future Fund , Janus Henderson Investors , Monashee Investment Management , Chief Executive Officer , Rachel Mears , Jeffrey Long Mcgie , Managing Director , Ridgeback Capital , Managing Partner , Syncona Investment Management Limited , Chief Business , Mark Swallow , Investor Relations , Aquell , Herapeutics , Raises , Billion , Oversubscribed , Series , Financing , Advance , Ioneering , Ulti , Odular , Engineered , Egulatory , Greg , Fell , Therapy , Pipeline , Platform ,